EUVIMEDEUVIMED entdecken
Crossref

First-line lenvatinib and sorafenib in RR-DTC from a shared real-life context

Vincenzo Marotta iD, Anna Tortora, Mariafelicia Valeriani, Alessia Caleo, Sara Gaeta, Teresa Infante, Francesco Stanzione, Luca Scafuri, Claudio Gambardella, Francesca Di Gennaro, Francesco Perri, Antongiulio Faggiano und 2 weitere

Endocrine-Related Cancer · 2025

DOI: 10.1530/erc-24-0215 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2025. Verfasst von Vincenzo Marotta und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy. Hauptthemen laut MEDLINE: Sorafenib, Phenylurea Compounds, Quinolines, Thyroid Neoplasms. Die Arbeit nennt 41 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The kinase inhibitors lenvatinib and sorafenib represent the first-line options for radioiodine-refractory differentiated thyroid cancer (RR-DTC). Comparative studies in the same study population or between similar cohorts are scarce. Our objective was to compare lenvatinib and sorafenib in naïve RR-DTC in a homogeneous real-life context. We performed a retrospective study involving two institutions from the Italian region Campania. Primary endpoints were progression-free survival (PFS) and overall survival (OS). Secondary endpoints were objective response rate (ORR), disease-control rate, adverse events graded ≥3, toxicity-related treatment withdrawal, and dose reductions/interruptions. Forty-eight RR-DTC patients were included (median follow-up 45.5 months): 24 received lenvatinib from 2015 to 2021 and 24 sorafenib from 2012 to 2016. The sorafenib group showed a higher disease-related symptoms rate ( P = 0.022), tumor burden ( P = 0.002), and cumulative radioiodine dose compared to lenvatinib. At univariate analysis, median PFS and OS were significantly longer for lenvatinib (30 and 53 months, respectively) compared to sorafenib (10 and 38 months, respectively) ( P < 0.001 and = 0.037, respectively). At multivariate analysis, the significance was retained for PFS and lost for OS. ORR was higher for lenvatinib compared to sorafenib ( P < 0.001). Dose reductions and interruptions were more frequent for lenvatinib compared to sorafenib ( P = 0.003 and 0.01, respectively). In our real-life context, RR-DTC treated with first-line sorafenib had more advanced disease compared to lenvatinib. Lenvatinib exerted stronger antitumor activity (improved PFS and ORR) compared to sorafenib but did not improve OS. Sorafenib was more manageable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SorafenibPhenylurea CompoundsQuinolinesThyroid NeoplasmsAntineoplastic AgentsProtein Kinase InhibitorsHumansFemaleMaleMiddle AgedRetrospective StudiesAgedAdultAged, 80 and over

Stichwörter der Autor:innen

kinase-inhibitorslenvatinibradioiodine-refractorysorafenibthyroid cancerthyroid neoplasmsthyroid nodules

Substanzen

lenvatinibSorafenibPhenylurea CompoundsQuinolinesAntineoplastic AgentsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medicine, Surgery and Dentistry, "Scuola Medica Salernitana", University of Salerno, Baronissi, Italy.
  • UOC Clinica Endocrinologica e Diabetologica, AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy.
  • UOC Chirurgia Generale, AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy.
  • UOC Anatomia Patologica, AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy.
  • Laboratorio di Diagnostica Molecolare, UOC Anatomia Patologica, AOU San Giovanni di Dio e Ruggi d'Aragona, Salerno, Italy.
  • UOC di Chirurgia Generale, d'Urgenza e di Endocrinochirurgia, Pineta Grande Hospital, Castel Volturno, Caserta, Italy.

ORCID-Profile: Vincenzo Marotta, Mario Vitale

Zitieren

APA

Marotta, V., Tortora, A., Valeriani, M., Caleo, A., Gaeta, S., Infante, T., Stanzione, F., Scafuri, L., Gambardella, C., Di Gennaro, F., Perri, F., Faggiano, A., Vitale, M., & Pezzullo, L. (2025). First-line lenvatinib and sorafenib in RR-DTC from a shared real-life context. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0215

Vancouver

Marotta V, Tortora A, Valeriani M, Caleo A, Gaeta S, Infante T, et al. First-line lenvatinib and sorafenib in RR-DTC from a shared real-life context. Endocrine-Related Cancer. 2025. doi:10.1530/erc-24-0215

BibTeX
@article{Marotta2025,
  author = {Marotta, Vincenzo and Tortora, Anna and Valeriani, Mariafelicia and Caleo, Alessia and Gaeta, Sara and Infante, Teresa and Stanzione, Francesco and Scafuri, Luca and Gambardella, Claudio and Di Gennaro, Francesca and Perri, Francesco and Faggiano, Antongiulio and Vitale, Mario and Pezzullo, Luciano},
  title = {First-line lenvatinib and sorafenib in RR-DTC from a shared real-life context},
  journal = {Endocrine-Related Cancer},
  year = {2025},
  doi = {10.1530/erc-24-0215}
}
Kostenlos starten →